A Concordance Study between Patient Acceptable Symptom State (PASS) and Disease Activity in Chronic Spontaneous Urticaria
Keywords:
chronic spontaneous urticaria (CSU), patient acceptable symptom state (PASS), the weekly urticaria activity score (UAS7)Abstract
Introduction: The Patient Acceptable Symptom State (PASS), a patient-reported outcome measure, has demonstrated correlations with disease severity in various conditions, including psoriasis and scleroderma. However, the clinical relevance of PASS in the context of chronic spontaneous urticaria (CSU) remains to be fully elucidated.
Objectives: This study aimed to determine the prevalence of PASS among CSU patients, identify potential predictors, and establish the weekly urticaria activity score (UAS7) threshold for PASS.
Methods: Demographic and clinical data from CSU patients were prospectively collected. PASS attainment was assessed using a single-item questionnaire. Logistic regression analysis and interaction effects analysis were employed to identify predictors associated with achieving PASS (PASS-Y) or failing to achieve PASS (PASS-N). The UAS7 threshold corresponding to PASS was determined through receiver operating characteristic (ROC) curve analysis.
Results: A total of 161 CSU patients were enrolled in this study. Among them, 70.5% exhibited non-severe disease activity (UAS7<28) and achieved PASS-Y. Logistic regression analysis revealed a significant association between UAS7 scores and PASS status (AOR=1.105, P<0.001). Female patients with severe disease activity (UAS7≥ 28) were significantly less likely to achieve PASS-Y compared to their male counterparts (AOR=3.514, P=0.042). ROC analysis identified a UAS7 threshold of 21.5 for predicting PASS, with an area under the curve (AUC) of 0.821.
Conclusions: In patients with CSU, PASS demonstrates a strong correlation with UAS7 scores and is straightforward to implement. It may serve as a valuable complementary tool to UAS7 in clinical settings, facilitating a rapid, patient-centered assessment of disease activity.
References
Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-7.
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-414.
Kolkhir P, Muñoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;149(6):1819-31.
Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184(2):226-36.
Sommer R, da Silva N, Langenbruch A, Maurer M, Staubach-Renz P, Augustin M. Characteristics and determinants of patient burden and needs in the treatment of chronic spontaneous urticaria. Eur J Dermatol. 2020;30(3):259-66.
O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197-201.
Kolkhir P, Gimenez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers. 2022;8(1):61.
Zhao Z, Zhang C, Jiang Y, et al. Chinese version of the chronic urticaria quality of life questionnaire: cultural adaptation, factor analysis, assessment of reliability and validity. Arch Dermatol Res. 2022;314(9):847-55.
Hawro T, Ohanyan T, Schoepke N, et al. The Urticaria Activity Score-Validity, Reliability, and Responsiveness. J Allergy Clin Immunol Pract. 2018;6(4):1185-90 e1.
Li J, Guo A, Chen W, et al. Association of ORAI1 gene polymorphisms with chronic spontaneous urticaria and the efficacy of the nonsedating H1 antihistamine desloratadine. J Allergy Clin Immunol. 2017;139(4):1386-8 e9.
Lubrano E, Scriffignano S, Azuaga AB, Ramirez J, Canete JD, Perrotta FM. Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. RMD Open. 2020;6(1).
Heiberg T, Kvien TK, Mowinckel P, Aletaha D, Smolen JS, Hagen KB. Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(7):967-71.
Maksymowych WP, Richardson R, Mallon C, van der Heijde D, Boonen A. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. Arthritis Rheum. 2007;57(1):133-9.
Maksymowych WP, Gooch K, Dougados M, et al. Thresholds of patient-reported outcomes that define the patient acceptable symptom state in ankylosing spondylitis vary over time and by treatment and patient characteristics. Arthritis Care Res (Hoboken). 2010;62(6):826-34.
Fei JZ, Perruccio AV, Ye JY, Gladman DD, Chandran V. The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis. Rheumatology (Oxford). 2020;59(1):69-76.
Arnold MB, Khanna D, Denton CP, et al. Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2018;57(1):152-7.
Wiriyakijja P, Porter S, Fedele S, et al. The patient acceptable symptom state in oral lichen planus: identification of cut-off threshold scores in measures of pain and quality of life. Clin Oral Investig. 2021;25(6):3699-709.
Huang Y, Gao L, Cheng H, et al. Difference of glucose and lipid metabolism abnormalities and body fat between the Chinese and USA teenagers. J Glob Health. 2023;13:04041.
Stull D, McBride D, Tian H, et al. Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria. Br J Dermatol. 2017;177(4):1093-101.
Balp MM, Vietri J, Tian H, Isherwood G. The Impact of Chronic Urticaria from the Patient's Perspective: A Survey in Five European Countries. Patient. 2015;8(6):551-8.
Neisinger S, Sousa Pinto B, Ramanauskaite A, et al. CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria. Clinical and Translational Allergy. 2024;14(1).
Wang Q, Lu W, Luo Y, et al. Relationship between patient acceptable symptom state and disease scores in psoriasis. J Dermatol. 2022;49(4):448-53.
Muller B, Yabroudi MA, Lynch A, et al. Defining Thresholds for the Patient Acceptable Symptom State for the IKDC Subjective Knee Form and KOOS for Patients Who Underwent ACL Reconstruction. Am J Sports Med. 2016;44(11):2820-6.
Maurer M, Gimenez-Arnau A, Ensina LF, Chu CY, Jaumont X, Tassinari P. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results. World Allergy Organ J. 2020;13(9):100460.
Maurer M, Ortonne JP, Zuberbier T. Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. Br J Dermatol. 2009;160(3):633-41.
Sanchez Borges M, Tassinari S, Flores A. [Epidemiologic features in patients with antihistamine-resistant chronic urticaria]. Rev Alerg Mex. 2015;62(4):279-86.
Erol K, Ertas SK, Ertas R. Fatigue Is Common and Predicted by Female Gender and Sleep Disturbance in Patients with Chronic Spontaneous Urticaria. J Allergy Clin Immunol Pract. 2021;9(1):469-76.
Tzur Bitan D, Berzin D, Cohen A. The association of chronic spontaneous urticaria (CSU) with anxiety and depression: a nationwide cohort study. Arch Dermatol Res. 2021;313(1):33-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Xinyu Shui, Yu Jiang, Cong Peng, Jiayi Wang, Qiaozhi Cao, Qiqi Jia, Shufang Liu, Jie Li
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
